173 related articles for article (PubMed ID: 23590161)
1. Sildenafil and cardioprotection.
Kukreja RC
Curr Pharm Des; 2013; 19(39):6842-7. PubMed ID: 23590161
[TBL] [Abstract][Full Text] [Related]
2. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.
Das A; Durrant D; Salloum FN; Xi L; Kukreja RC
Pharmacol Ther; 2015 Mar; 147():12-21. PubMed ID: 25444755
[TBL] [Abstract][Full Text] [Related]
3. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
4. The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats.
Küçük A; Yucel M; Erkasap N; Tosun M; Koken T; Ozkurt M; Erkasap S
Mol Biol Rep; 2012 Oct; 39(10):9775-82. PubMed ID: 22736111
[TBL] [Abstract][Full Text] [Related]
5. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Kukreja RC
Br J Pharmacol; 2007 Mar; 150(5):538-40. PubMed ID: 17245364
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
[TBL] [Abstract][Full Text] [Related]
8. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
[TBL] [Abstract][Full Text] [Related]
9. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
10. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
11. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
Lowe G; Costabile RA
J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
[TBL] [Abstract][Full Text] [Related]
12. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
[TBL] [Abstract][Full Text] [Related]
13. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
[TBL] [Abstract][Full Text] [Related]
14. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193
[No Abstract] [Full Text] [Related]
15. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotection with sildenafil: implications for clinical practice.
Raja SG
Curr Med Chem; 2006; 13(26):3155-64. PubMed ID: 17168704
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
18. Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.
Rust KY; Wilkens H; Kaiser R; Bregel D; Wilske J; Kraemer T
Ther Drug Monit; 2012 Dec; 34(6):729-35. PubMed ID: 23128911
[TBL] [Abstract][Full Text] [Related]
19. Adulteration of purported herbal and natural sexual performance enhancement dietary supplements with synthetic phosphodiesterase type 5 inhibitors.
Campbell N; Clark JP; Stecher VJ; Thomas JW; Callanan AC; Donnelly BF; Goldstein I; Kaminetsky JC
J Sex Med; 2013 Jul; 10(7):1842-9. PubMed ID: 23634714
[TBL] [Abstract][Full Text] [Related]
20. PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update.
Gur S; Kadowitz PJ; Serefoglu EC; Hellstrom WJ
Curr Pharm Des; 2012; 18(34):5590-606. PubMed ID: 22747425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
